Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Abstract

Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization of clonal architecture is essential to understand the evolutionary history of tumor development and its association with treatment resistance. Here, using a single-cell DNA sequencing, we report the clonal architecture and mutational histories of 123 acute myeloid leukemia (AML) patients. The single-cell data reveals cell-level mutation co-occurrence and enables reconstruction of mutational histories characterized by linear and branching patterns of clonal evolution, with the latter including convergent evolution. Through xenotransplantion, we show leukemia initiating capabilities of individual subclones evolving in parallel. Also, by simultaneous single-cell DNA and cell surface protein analysis, we illustrate both genetic and phenotypic evolution in AML. Lastly, single-cell analysis of longitudinal samples reveals underlying evolutionary process of therapeutic resistance. Together, these data unravel clonal diversity and evolution patterns of AML, and highlight their clinical relevance in the era of precision medicine.

References 40

1. 1.

   McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613-628.

   Not in our library10.1016/j.cell.2017.01.018

2. 2.

   Welch JS, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264-278.

   Not in our library10.1016/j.cell.2012.06.023

3. 3.
   The Life History of 21 Breast Cancers · 2012

   Corrected
4. 4.

   Strino F, Parisi F, Micsinai M, Kluger Y. TrAp: a tree approach for fingerprinting subclonal tumor composition. Nucleic Acids Res. 2013;41:e165.

   Not in our library10.1093/nar/gkt641

5. 5.

   Paguirigan AL, et al. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci. Transl. Med. 2015;7:281re282.

   Not in our library10.1126/scitranslmed.aaa0763

6. 6.

   Wang Y, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155.

   Not in our library10.1038/nature13600

7. 7.

   Potter N, et al. Single cell analysis of clonal architecture in acute myeloid leukaemia. Leukemia. 2019;33:1113-1123.

   Not in our library10.1038/s41375-018-0319-2

8. 8.

   Navin N, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90.

   Not in our library10.1038/nature09807

9. 9.

   Eirew P, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015;518:422-426.

   Not in our library10.1038/nature13952

10. 10.

    Wang Y, Navin NE. Advances and applications of single-cell sequencing technologies. Mol. Cell. 2015;58:598-609.

    Not in our library10.1016/j.molcel.2015.05.005

11. 11.
    High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics · 2018

    No notice
12. 12.

    Takahashi K, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18:100-111.

    Not in our library10.1016/s1470-2045(16)30626-x

13. 13.

    Shouval R, et al. Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis. Exp. Hematol. 2014;42:457-463.

    Not in our library10.1016/j.exphem.2014.01.010

14. 14.

    Lindsley RC, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N. Engl. J. Med. 2017;376:536-547.

    Not in our library10.1056/nejmoa1611604

15. 15.
    PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy · 2018

    No notice
16. 16.

    Awada H, et al. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv. 2019;3:339-349.

    Not in our library10.1182/bloodadvances.2018024216

17. 17.

    Ho PA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group. Blood. 2010;116:702-710.

    Not in our library10.1182/blood-2010-02-268953

18. 18.

    Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat. Rev. Cancer. 2015;15:152-165.

    Not in our library10.1038/nrc3895

19. 19.
    Tree inference for single-cell data · 2016

    No notice
20. 20.

    Campbell PJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109-1113.

    Not in our library10.1038/nature09460

21. 21.

    Malikic S, Jahn K, Kuipers J, Sahinalp SC, Beerenwinkel N. Integrative inference of subclonal tumour evolution from single-cell and bulk sequencing data. Nat. Commun. 2019;10:2750.

    Not in our library10.1038/s41467-019-10737-5

22. 22.

    Falini B, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 2005;352:254-266.

    Not in our library10.1056/nejmoa041974

23. 23.

    Chou WC, et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia. 2011;25:246-253.

    Not in our library10.1038/leu.2010.267

24. 24.

    Shlush LI, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328-333.

    Not in our library10.1038/nature13038

25. 25.

    Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015;29:2390-2392.

    Not in our library10.1038/leu.2015.165

26. 26.

    Amatangelo MD, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130:732-741.

    Not in our library10.1182/blood-2017-04-779447

27. 27.

    Quek L, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat. Med. 2018;24:1167-1177.

    Not in our library10.1038/s41591-018-0115-6

28. 28.

    McMahon CM, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9:1050-1063.

    Not in our library10.1158/2159-8290.cd-18-1453

29. 29.

    Anderson K, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2010;469:356.

    Not in our library10.1038/nature09650

30. 30.

    Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012;366:883-892.

    Not in our library10.1056/nejmoa1113205

31. 31.

    Yates LR, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 2015;21:751-759.

    Not in our library10.1038/nm.3886

32. 32.

    Klco JM, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25:379-392.

    Not in our library10.1016/j.ccr.2014.01.031

33. 33.

    van Galen P, et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265-1281 e1224.

    Not in our library10.1016/j.cell.2019.01.031

34. 34.

    Gaiti F, et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019;569:576-580.

    Not in our library10.1038/s41586-019-1198-z

35. 35.

    Nam AS, et al. Somatic mutations and cell identity linked by genotyping of transcriptomes. Nature. 2019;571:355-360.

    Not in our library10.1038/s41586-019-1367-0

36. 36.

    Zafar H, Wang Y, Nakhleh L, Navin N, Chen K. Monovar: single-nucleotide variant detection in single cells. Nat. Methods. 2016;13:505-507.

    Not in our library10.1038/nmeth.3835

37. 37.

    Van Loo P, et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA. 2010;107:16910-16915.

    Not in our library10.1073/pnas.1009843107

38. 38.

    Shah MV, et al. Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia. Biol. Blood Marrow Transplant. 2018;24:1514-1520.

    Not in our library10.1016/j.bbmt.2018.02.003

39. 39.

    Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 1995;57:289-300.

    Not in our library

40. 40.

    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452-458.

    Not in our library10.1038/bmt.2012.244

Cited by papers we hold 8

• CAR-T cell therapy for cancer: current challenges and future directions · 2025
  No notice
• A new genomic framework to categorize pediatric acute myeloid leukemia · 2024
  No notice
• Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution · 2023
  No notice
• Molecular testing for acute myeloid leukemia · 2022
  Not checked
• Detection of early seeding of Richter transformation in chronic lymphocytic leukemia · 2022
  No notice
• Haematopoietic ageing through the lens of single-cell technologies · 2021
  Not checked
• Spatial structure governs the mode of tumour evolution · 2021
  No notice
• High throughput single-cell detection of multiplex CRISPR-edited gene modifications · 2020
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.